Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Moshe Weiss

Pediatric Endocrinology Spring Valley, NY Medical Doctor

NPI 1083683163 CMS profile 185382

258 Old Nyack Turnpike, Spring Valley, NY 10977

Open in the dashboard

General payments

$2,650

105 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Moshe Weiss of Spring Valley, NY is reported in the CMS Open Payments database as having received $2,650 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $332 12
2024 General $378 15
2023 General $548 21
2022 General $287 11
2021 General $356 14
2020 General $391 16
2019 General $358 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Moshe Weiss
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Moshe Weiss were reported at $332. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Moshe Weiss Pediatric Endocrinology median Middle half National median
2019 $358 $196 $68–$845 $163
2020 $391 $124 $37–$722 $114
2021 $356 $134 $35–$691 $132
2022 $287 $177 $47–$726 $149
2023 $548 $236 $75–$887 $160
2024 $378 $259 $91–$979 $164
2025 $332 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $547 20 payments
  2. Ascendis Pharma, Inc. $407 13 payments
  3. Amneal Pharmaceuticals LLC $390 17 payments
  4. Pfizer Inc. $264 11 payments
  5. CutisPharma, Inc. $262 11 payments
  6. TOLMAR Pharmaceuticals, Inc. $150 5 payments
  7. Novo Nordisk Inc $142 6 payments
  8. Tolmar, Inc. $81 3 payments
  9. Endo Pharmaceuticals Inc. $76 4 payments
  10. Endo USA, Inc. $64 3 payments
  11. Other $267 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,576 103 payments
  2. Education $74 2 payments
Products named General payments · program years 2019–2025
  1. SKYTROFA $407 13 payments
  2. UNITHROID $390 17 payments
  3. LUPRON DEPOT $297 12 payments
  4. GENOTROPIN $264 11 payments
  5. SYNTHROID $177 4 payments
  6. FENSOLVI $158 5 payments
  7. Triptodur Pediatrics/Neonatology $142 6 payments
  8. NGENLA $137 5 payments
  9. TRIPTODUR Endocrinology $120 5 payments
  10. SUPPRELIN $115 6 payments
  11. Other $543 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record